Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2)....

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Changhai, Qian, Kewen, Li, Tian, Zhang, Sheng, Fu, Wenyan, Ding, Min, Hu, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265355/
https://www.ncbi.nlm.nih.gov/pubmed/32332765
http://dx.doi.org/10.1038/s41467-020-16048-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265355/
https://www.ncbi.nlm.nih.gov/pubmed/32332765
http://dx.doi.org/10.1038/s41467-020-16048-4

Ejemplares similares